CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of ...
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress Rolling NDA submission for zuranolone in MDD expected to begin in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback